Yanmei Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yanmei Huang has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
- Russell W. Madison
Foundation Medicine, Cambridge, Massachusetts
20 shared publications - Christian Rolfo
The Ohio State University Comprehensive Cancer Center, The Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), Columbus, OH, USA
19 shared publications - Derek W. Brown
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD, USA
19 shared publications - Geoffrey R. Oxnard
Eli Lilly and Company, Indianapolis, Indiana
19 shared publications - Hatim Husain
UC San Diego, La Jolla, USA
19 shared publications - Jason D. Hughes
Foundation Medicine, Inc., Cambridge, Massachusetts
19 shared publications
Latest Publications
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay
PURPOSE: There is increasing interest in organ preservation for early-stage rectal cancer. Circulating tumor DNA (ctDNA) for detection of molecular residual disease may aid in clinical decision making for these approaches. METHODS: The Canadian Cancer Trials Group (CCTG) CO.28 NEO trial was a phase II study of 58 patients with early-stage, clinically node-negative rectal cancers exploring the impact of 3 months of neoadjuvant infusional fluorouracil, leucovorin, and oxaliplatin or capecitabine and oxaliplatin chemotherapy followed by transanal excision surgery (TES) in patients with treatment-responsive tumors. Patients without a clinical response were recommended total mesorectal excision (TME). A total of 52 patients had blood available for retrospective ctDNA analysis with the tumor-informed ctDNA assay FoundationOneTracker. Blood samples were taken prechemotherapy, postchemotherapy but before TES and/or TME, on surveillance (months 12, 24, and 46), and at progression. RESULTS: ctDNA was detected in 24.5% of patients before chemotherapy and detection increased with clinical T stage ( P = .022). The ctDNA detection rate decreased to 6.7% of patients postchemotherapy but pre-TES ( P = .024). Two thirds of patients with ctDNA detected after neoadjuvant chemotherapy (66.7%) had been recommended TME based on lack of clinical response or TES pathology. Of patients (n = 3) with a sample taken at the time of progression, 33.3% (n = 1) had detectable ctDNA; however, no surveillance samples had ctDNA detected for any patient who had a clinical recurrence. CONCLUSION: Early-stage node-negative rectal cancers shed ctDNA that can be detected in a subset of patients, particularly those with a higher clinical stage. This offers a potential future decision aid to augment endoscopy and MRI, particularly in cases of clinical uncertainty. More data in larger studies with denser surveillance sampling are needed to support ctDNA integration into clinical decision making for organ preservation.
- 1 December 2025
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Detection of Molecular Residual Disease by Circulating Tumor DNA in Early-Stage Node-Negative Rectal Cancers (CCTG CO.28) Using a Tumor-Informed Assay
PURPOSE: There is increasing interest in organ preservation for early-stage rectal cancer. Circulating tumor DNA (ctDNA) for detection of molecular residual disease may aid in clinical decision making for these approaches. METHODS: The Canadian Cancer Trials Group (CCTG) CO.28 NEO trial was a phase II study of 58 patients with early-stage, clinically node-negative rectal cancers exploring the impact of 3 months of neoadjuvant infusional fluorouracil, leucovorin, and oxaliplatin or capecitabine and oxaliplatin chemotherapy followed by transanal excision surgery (TES) in patients with treatment-responsive tumors. Patients without a clinical response were recommended total mesorectal excision (TME). A total of 52 patients had blood available for retrospective ctDNA analysis with the tumor-informed ctDNA assay FoundationOneTracker. Blood samples were taken prechemotherapy, postchemotherapy but before TES and/or TME, on surveillance (months 12, 24, and 46), and at progression. RESULTS: ctDNA was detected in 24.5% of patients before chemotherapy and detection increased with clinical T stage ( P = .022). The ctDNA detection rate decreased to 6.7% of patients postchemotherapy but pre-TES ( P = .024). Two thirds of patients with ctDNA detected after neoadjuvant chemotherapy (66.7%) had been recommended TME based on lack of clinical response or TES pathology. Of patients (n = 3) with a sample taken at the time of progression, 33.3% (n = 1) had detectable ctDNA; however, no surveillance samples had ctDNA detected for any patient who had a clinical recurrence. CONCLUSION: Early-stage node-negative rectal cancers shed ctDNA that can be detected in a subset of patients, particularly those with a higher clinical stage. This offers a potential future decision aid to augment endoscopy and MRI, particularly in cases of clinical uncertainty. More data in larger studies with denser surveillance sampling are needed to support ctDNA integration into clinical decision making for organ preservation.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 4: Positive percent agreement (PPA) and negative predictive value (NPV) of liquid biopsy collected no more than 90 days after tissue biopsy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 4: Positive percent agreement (PPA) and negative predictive value (NPV) of liquid biopsy collected no more than 90 days after tissue biopsy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 1: Paired tissue and liquid biopsy specimens were used to assess sensitivity (PPA), negative predictive value (NPV), and specificity (NPA) for detection of driver alterations in multiple cancer types.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 1: Paired tissue and liquid biopsy specimens were used to assess sensitivity (PPA), negative predictive value (NPV), and specificity (NPA) for detection of driver alterations in multiple cancer types.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 1: Paired tissue and liquid biopsy specimens were used to assess sensitivity (PPA), negative predictive value (NPV), and specificity (NPA) for detection of driver alterations in multiple cancer types.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 1: Paired tissue and liquid biopsy specimens were used to assess sensitivity (PPA), negative predictive value (NPV), and specificity (NPA) for detection of driver alterations in multiple cancer types.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 2: Positive percent agreement (PPA) and negative predictive value (NPV) of liquid biopsy collected no more than 30 days after tissue biopsy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 2: Positive percent agreement (PPA) and negative predictive value (NPV) of liquid biopsy collected no more than 30 days after tissue biopsy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 5: Above 1%, concordance of paired tissue and liquid biopsy specimens was universally high across ctDNA TF ranges.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 5: Above 1%, concordance of paired tissue and liquid biopsy specimens was universally high across ctDNA TF ranges.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 2: Positive percent agreement (PPA) and negative predictive value (NPV) of liquid biopsy collected no more than 30 days after tissue biopsy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 2: Positive percent agreement (PPA) and negative predictive value (NPV) of liquid biopsy collected no more than 30 days after tissue biopsy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Table 1: Clinical, demographic, and genomic features for patients treated in the first line following negative liquid biopsy CGP and subsequent positive tissue CGP.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Table 1: Clinical, demographic, and genomic features for patients treated in the first line following negative liquid biopsy CGP and subsequent positive tissue CGP.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 7: KRAS mutations detected in tissue biopsy from patients which were excluded from figure 5B and not considered eligible for targeted therapy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 7: KRAS mutations detected in tissue biopsy from patients which were excluded from figure 5B and not considered eligible for targeted therapy.
- Open Access
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 7: KRAS mutations detected in tissue biopsy from patients which were excluded from figure 5B and not considered eligible for targeted therapy.
- 3 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Measurement of ctDNA Tumor Fraction Identifies Informative Negative Liquid Biopsy Results and Informs Value of Tissue Confirmation
Supplementary Figure 7: KRAS mutations detected in tissue biopsy from patients which were excluded from figure 5B and not considered eligible for targeted therapy.